Atopobium vaginae as Next Generation Probiotics
Background A. vaginae for Cancer Highlights Products FAQs Resources
The novel drug discovery strategies have aroused great attention in some clinical settings. To meet the challenging requirements, Creative Biolabs has built a team of experienced scientists with facilities and processes designed specifically to provide the best strategy and protocols for next-generation probiotics (NGPs) services based on Atopobium vaginae. We have accomplished several projects and have several Atopobium vaginae - based live biotherapeutics drugs under development.
Introduction to Atopobium vaginae
Atopobium vaginae, a member of the family Coriobacteriaceae, is a gram-positive bacterium that has been associated with many bacterial infections in humans, including bacterial vaginosis (BV) in women. In general, Atopobium vaginae is a type of facultative anaerobe and often exists as single or pairs of short chains. Till now, different strains of Atopobium vaginae, such as CCUG 44061, CCUG 44116, CCUG 42099, and CCUG 38953T, have been isolated from specific vaginal samples. Moreover, pilot studies have shown that Atopobium vaginae are a key component for BV biofilms and its resistance to certain antimicrobials should be a major issue for improving the treatment efficacy in BV patients. Besides, numerous data have indicated that the Atopobium vaginae play an important role in preventing or treating human diseases. As a result, the Atopobium vaginae has been widely used as a new class of NGPs in specific disease treatments.
Fig.1 Atopobium vaginae culture, Gram stain, magnification 100×.1
Atopobium vaginae for Cancer Treatment
Recent researchers have revealed that Atopobium vaginae are an attractive biotherapeutic agent against many disease types. Based on our integrated Live Biotherapeutics Drug Discovery platform, Creative Biolabs now offers a collection of Atopobium vaginae - based services to develop novel therapies targeting various diseases, especially for endometrial cancer.
Endometrial cancer is a kind of cancer that starts from the uterus or womb. Endometrial cancer is usually related to abnormal cell growth in the human body. Several risk factors, such as obesity and diabetes, have been confirmed that can cause the occurrence of endometrial cancer. Currently, endometrial cancer has been classified into several subtypes based on histologic properties, including adenocarcinoma, squamous cell carcinoma, and serous carcinoma. Among them, adenocarcinoma is the most common type and has been identified in almost 80% of patients with endometrial cancer. The optimal options for treating endometrial cancer are hysterectomy, chemotherapy, and hormone therapy. In recent studies, novel live biotherapeutics targeting Atopobium vaginae have been generated for the treatment of endometrial cancer. The data derived from mice models have indicated that these drugs can inhibit tumor proliferation and induce the apoptosis of endometrial cancer cells.
Highlights of Atopobium vaginae Drug Discovery Services
By continuing to grow in response to the requirements of our clients, Creative Biolabs is dedicated to exploring novel and innovative NGPs to offer a battery of live biotherapeutic biological drug development solutions. We are proud to partner with our clients on the journey of bringing novel live biotherapeutics to the market.
-
Experienced scientists to meet your requirements
-
Advanced technology to support your projects
-
Strong sense of purpose to push the project forward
-
Innovative approaches to solving any problems
Creative Biolabs utilizes unrivaled, proprietary services, advanced project life-cycle management, as well as real-time data to ensure ideal outcomes. Through our full spectrum of early discovery, nonclinical, and commercialization services, we are committed to providing the most promising Atopobium vaginae solutions for our clients. For more detailed information, please feel free to contact us.
Related Products
|
CAT
|
PRODUCT NAME
|
PRODUCT OVERVIEW
|
|
LBST-073FG
|
Atopobium Vaginae
|
Atopobium Vaginae was isolated from the vaginal flora of a healthy woman. It is a Gram-positive facultative anaerobic bacterial species.
|
Frequently Asked Questions
What distinguishes A. vaginae in probiotic research?
A. vaginae is gaining attention in probiotic research due to its unique presence in the vaginal microbiota. Its potential in maintaining vaginal health and preventing dysbiosis is central to its interest as a next-generation probiotic candidate.
What services are offered for A. vaginae probiotic discovery?
The A. vaginae probiotic discovery service includes the identification and characterization of strains, assessment of their probiotic functions, safety evaluations, and high-throughput screening to facilitate research into probiotic therapies.
Is there a safety profile available for A. vaginae strains?
Safety is a paramount consideration in probiotic research. Available services include a thorough safety assessment of A. vaginae strains, ensuring they are suitable for research and development purposes.
Resources
Reference
-
Mendling, Werner, et al. "An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review." Archives of gynecology and obstetrics 300 (2019): 1-6.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
